Explore the evolution to personalized treatment of IBD

Dr. David T. Rubin

The individualization of therapy in IBD

Dr. David T. Rubin discusses evaluating and treating patients with IBD in his practice.

8 minutes

Watch

Multifaceted approach discussion

A multifaceted approach to treating IBD

Education, disease management, and more form part of comprehensive IBD treatment.

3 minutes

Review

Peer perspective

How do you primarily assess the effectiveness of a treatment in your patients with moderate to severe ulcerative colitis?

Next question

Peer perspective

Please evaluate this statement: “Cost to my patient is an important consideration in my IBD treatment decisions.”

Next question

Peer perspective

What is your biggest barrier to prescribing a biologic for the treatment of UC or CD?

Finish survey

$5.5 billion annually

Annual indirect costs of IBD are estimated at $5.5 billion in the United States, between €1.4 billion and €16.5 billion in Europe, and more than $1 billion in Canada.85-88

Biologic infusion

Considerations in IBD management

Current topics of research in IBD include disease severity and duration at initiation of treatment, and the burden of suboptimal therapy.

4 minutes

Read

The role of lymphocyte trafficking in IBD

Lymphocyte trafficking to the gut involves a multistep adhesion cascade process.

6 minutes

Read

Personalized approach to IBD

Treat-to-target as a strategy combines regular assessment of disease activity with a protocol in which therapeutic consequences and targets are predefined.

2 minutes

Read

Join IBD Insights

Gain access to members-only content and downloadable resources about IBD.

Join

IBD’s impact on patient quality of life

IBD is associated with substantial physical and emotional burdens for patients.

3 minutes

Read

Therapeutic options discussion

Therapeutic options and treatment response

Efficacy, safety, and patient response are some of the key considerations when reviewing IBD treatment options.

4 minutes

Read

IBD management and goals

Key IBD management goals continue to change to better address long-term disease progression and outcomes.

3 minutes

Read

IBD etiology

The etiology of IBD: Potential causes and factors

While the causes of IBD are unknown, several studies have suggested a variety of hypotheses.

2 minutes

Read

The pathophysiology of IBD

Defects in normal gut immunity may contribute inappropriate inflammatory responses characteristic of IBD.

5 minutes

Read

Reviewing IBD demographics

A look at the worldwide demographics of IBD

IBD is a global phenomenon, affecting a significant proportion of the population in the Americas and Europe, as well as Africa and Asia.

2 minutes

Read

Normal gastrointestinal tract physiology

The normal GI tract is a tightly controlled environment designed to elicit appropriate immune responses.

2 minutes

Read

Gut close-up

Differentiating between UC and CD

UC and CD share several clinical features, characterized by chronic GI tract inflammation.

2 minutes

Read

Reviewing IBD economics

The economic burden of IBD

The worldwide public health burden of IBD, including economic costs, is estimated to be billions of dollars yearly.

2 minutes

Review

+ Show references

  1. Yarur AJ, Strobel SG, Deshpande AR, Abreu MT. Gastroenterol Hepatol (N Y). 2011;7:652-659.
  2. Solberg IC, Høivik ML, Cvancarova M, Moum B; IBSEN Study Group. Scand J Gastroenterol. 2015;50:1456-1462.
  3. Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Am J Gastroenterol. 2014;109:994-1004.
  4. Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Gastroenterology. 2015;149:238-245.
  5. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2010;105:501-523; quiz 524.
  6. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Am J Gastroenterol. 2009;104:465-483; quiz 464, 484.
  7. Bouguen G, Levesque BG, Feagan BG, et al. Clin Gastroenterol Hepatol. 2015;13:1042-1050.
  8. Rubin DT, Cleveland NK. Am J Gastroenterol. 2015;110(9):1252-1256.
  9. Yanai H, Hanauer SB. Am J Gastroenterol. 2011;106:685-698.
  10. Lin MV, Blonski W, Lichtenstein GR. Expert Rev Gastroenterol Hepatol. 2010;4:167-180.
  11. Ahmed S, et al. Curr Gastroenterol Rep. 2015;17:14.
  12. Sandborn WJ, et al. J Crohns Colitis. 2013;7:958-967.
  13. Schreiber S, et al. J Crohns Colitis. 2013;7:213-221.
  14. Colombel JF, et al. N Engl J Med. 2010;362:1383-1395.
  15. Panaccione R, et al. Gastroenterology. 2014;146:392-400.e3.
  16. D’Haens G, et al. Lancet. 2008;371:660-667.
  17. Salmi M, et al. Immunol Rev. 2005;206:100-113.
  18. Banchereau J, et al. Nature. 1998;392:245-252.
  19. von Andrian UH, et al. N Engl J Med. 2000;343:1020-1034.
  20. Sheridan BS, Lefrançois L. Nat Immunol. 2011;12(6):485-491.
  21. Butcher EC. Cell. 1991;67:1033-1036.
  22. Koenecke C, et al. Expert Opin Ther Targets. 2009;13:297-306.
  23. Svensson M, et al. J Clin Invest. 2002;110:1113-1121.
  24. Wagner N, et al. Nature. 1996;382:366-370.
  25. Yoshie O, Imai T, Nomiyama H. Adv Immunol. 2001;78:57-110.
  26. Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T. Ann N Y Acad Sci. 2009;1173:350-356.
  27. Briskin M, et al. Am J Pathol. 1997;151:97-110.
  28. Ghosh S, et al. J Crohns Colitis. 2007;1:10-20.
  29. Fuller-Thomson E, et al. Inflamm Bowel Dis. 2006;12:697-707.
  30. Van Limbergen J, et al. Gastroenterology. 2008;135:1114-1122.
  31. Crohn’s and Colitis Foundation of America. 2014. IBD Fact Book. http://www.ccfa.org/assets/pdfs/ibdfactbook.pdf. Accessed August 2, 2016.
  32. Herzer M, et al. J Pediatr Gastroenterol Nutr. 2011;52:295-299.
  33. National Institute of Diabetes and Digestive and Kidney Diseases. 2014. https://www.niddk.nih.gov/health-information/health-topics/digestive-diseases/crohns-disease/Pages/all-content.aspx. Accessed September 1, 2016.
  34. National Institute of Diabetes and Digestive and Kidney Diseases. 2014. https://www.niddk.nih.gov/health-information/health-topics/digestive-diseases/ulcerative-colitis/Documents/UlcerativeColitis_508.pdf. Accessed September 1, 2016.
  35. Hanauer SB, et al. Lancet. 2002;359:1541-1549.
  36. Peyrin-Biroulet L, et al. Aliment Pharmacol Ther. 2011;33:870-879.
  37. Sutherland LR, et al. Cochrane Database Syst Rev. 2006;2:CD000544.
  38. Vermeire S, et al. Aliment Pharmacol Ther. 2006;25:3-12.
  39. Pariente B, et al. Inflamm Bowel Dis. 2011;17:1415-1422.
  40. Baars JE, et al. Inflamm Bowel Dis. 2012;18:1634-1640.
  41. Ochsenkühn T, et al. Gut. 2011;60:1294-1299.
  42. Moum B, et al. Am J Gastroenterol. 1999;94:1564-1569.
  43. Niv Y, et al. Am J Gastroenterol. 1987;82:1046-1051.
  44. Thia K, et al. Gastroenterology. 2010;139:1147-1155.
  45. Gisbert JP, et al. Inflamm Bowel Dis. 2009;15:1190-1198.
  46. Hefti MM, et al. Dis Colon Rectum. 2009;52:193-197.
  47. Rutter M, et al. Gastroenterology. 2004;126:451-459.
  48. Mowat C, et al. Gut. 2011;60:571-607.
  49. Crohn’s and Colitis Foundation of America. http://www.ccfa.org/assets/pdfs/surgery_brochure_final.pdf. Accessed September 1, 2016.
  50. Olaison G, et al. Gut. 1992;33:331-335.
  51. Rubin DT, et al. Inflamm Bowel Dis. 2009;15:581-588.
  52. Bjorkesten CG, et al. Scand J Gastroenterol. 2013;48:543-551.
  53. Yokoyama K, et al. Gastroenterol Res Pract. 2013;2013:192794.
  54. Siegel CA. Gut. 2012;61:459-465.
  55. Ananthakrishnan AN. Nat Rev Gastroenterol Hepatol. 2015;12:205-217.
  56. Jostins L, et al. Nature. 2012;491:119-124.
  57. Vermeire S, et al. Curr Opin Gastroenterol. 2011;27:32-37.
  58. Crohn’s and Colitis Foundation of America. 2009. http://www.ccfa.org/what-are-crohns-and-colitis/what-is-crohns-disease. Accessed September 1, 2016.
  59. Hanauer S. Inflamm Bowel Dis. 2006;12(Suppl 1):S3-S9.
  60. Sartor RB. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
  61. Shih DQ, et al. Curr Gastroenterol Rep. 2009;11:473-480.
  62. Sewell GW, et al. Curr Opin Immunol. 2009;21:506-513.
  63. Abraham C, et al. N Engl J Med. 2009;361:2066-2078.
  64. Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK. Gastroenterology. 1992;103(3):840-847.
  65. Esposito E, et al. Curr Med Chem. 2009;16:3152-3167.
  66. Perrier C, et al. Immunotherapy. 2011;3:1341-1352.
  67. Picker LJ, et al. Annu Rev Immunol. 1992;10:561-591.
  68. Ghosh S, et al. Ther Adv Gastroenterol. 2010;3:239-258.
  69. Ghosh S. Ann Rheum Dis. 2003;62(suppl II):ii70-ii72.
  70. Berlin C, et al. Cell. 1995;80:413-422.
  71. Sandborn WJ, et al. Am J Gastroenterol. 2003;98:2372-2382.
  72. Springer TA. Cell. 1994;76:301-314.
  73. Knigge KL. Clin Cornerstone. 2002;4:49-60.
  74. Eksteen B, et al. Inflamm Bowel Dis. 2008;14:1298-1312.
  75. Loftus EV Jr. Gastroenterology. 2004;126:1504-1517.
  76. The Crohn’s and Colitis Foundation of Canada. http://www.isupportibd.ca/pdf/ccfc.ca-impact-report-fast-facts.pdf. Accessed September 1, 2016.
  77. Crohn’s and Colitis Foundation of America. 2012. http://www.ccfa.org/resources/epidemiology.html. Accessed September 1, 2016.
  78. Kappelman MD, et al. Clin Gastroenterol Hepatol. 2007;5:1424-1429.
  79. European Crohn’s and Colitis Organisation. https://www.ecco-ibd.eu/index.php/public-affairs/press-awareness.html. Accessed September 1, 2016.
  80. Mowat AM. Nat Rev Immunol. 2003;3:331-341.
  81. McGuckin MA, et al. Inflamm Bowel Dis. 2009;15:100-113.
  82. Adams DH, et al. Gut. 2008;57:838-848.
  83. Podolsky DK. N Engl J Med. 2002;347:417-429.
  84. Eaden JA, et al. Gut. 2001;48:526-535.
  85. Park KT, et al. Inflamm Bowel Dis. 2011;17:1603-1609.
  86. Yu AP, et al. Curr Med Res Opin. 2008;24:319-328.
  87. Cohen RD, et al. Aliment Pharmacol Ther. 2010;31:693-707.
  88. Canadian Digestive Health Foundation. http://www.cdhf.ca/en/statistics. Accessed September 1, 2016.
  89. Sandborn WJ, et al. J Crohns Colitis. 2014;8:927-935.
  90. Crohn’s and Colitis Foundation of America. http://crohn-colitis.hu/pdf/history-of-ibd.pdf. Accessed September 1, 2016.
  91. Moss AC. Gastroenterol Rep (Oxf). 2015;3:63-68.
  92. Raine T. United European Gastroenterol J. 2014;2:333-344.
  93. Crohn’s and Colitis Foundation of America. http://www.ccfa.org/resources/corticosteroids.html. Accessed September 1, 2016.
  94. American Gastroenterological Association. https://www.gastro.org/practice/quality-initiatives/IBD_Measures.pdf. Accessed September 1, 2016.
  95. De Silva PS, et al. Aliment Pharmacol Ther. 2012;36:459-466.
  96. Hanauer SB. Aliment Pharmacol Ther. 2008;27(Suppl 1):15-21.
  97. Latella G, et al. World J Gastroenterol. 2012;18:3790-3799.
  98. Xavier RJ, et al. Nature. 2007;448:427-434.
  99. Rubin DT, et al. Aliment Pharmacol Ther. 2014;39:1143-1155.